dacomitinib

Back to Drugs List

Associated Genetic Biomarkers

Associated Diseases

Overview

Generic Name(s):

dacomitinib

Trade Name(s):

Vizimpro

NCI Definition [1]:

A highly selective, orally bioavailable small-molecule inhibitor of the HER family of tyrosine kinases with potential antineoplastic activity. Dacomitinib specifically and irreversibly binds to and inhibits human Her-1, Her-2, and Her-4, resulting in the proliferation inhibition and apoptosis of tumor cells that overexpress these receptors.

Biomarker-Directed Therapies

Dacomitinib can be used in the treatment of non-small cell lung carcinoma. EGFR, EGFR A763_Y764insFQEA, and EGFR Exon 19 Deletion are the most frequent biomarker inclusion criteria for use of dacomitinib [2].

Non-Small Cell Lung Carcinoma +

Disease is predicted to be sensitive to dacomitinib: -

Biomarker Criteria:

Sample must match one or more of the following:

EGFR Exon 19 Deletion, EGFR L858R

Clinical Setting(s): Metastatic (FDA, NCCN)

Biomarker Criteria:

Sample must match one or more of the following:

EGFR Exon 19 Deletion, EGFR L858R

Clinical Setting(s): Metastatic (FDA, NCCN)

Biomarker Criteria:

Sample must match one or more of the following:

EGFR G719A, EGFR G719C, EGFR G719S, EGFR L861Q, EGFR S768I

Sensitizing EGFR Mutations in Lung Cancer

Clinical Setting(s): Metastatic (NCCN)

Biomarker Criteria:

Sample must match one or more of the following:

EGFR G719A, EGFR G719C, EGFR G719S, EGFR L861Q, EGFR S768I

Sensitizing EGFR Mutations in Lung Cancer

Clinical Setting(s): Metastatic (NCCN)

Disease is predicted to be resistant to dacomitinib: -

Biomarker Criteria:

Sample must match all of the following:

EGFR T790M

Sample must match one or more of the following:

EGFR Sensitizing Mutations

Clinical Setting(s): Metastatic (NCCN)

Note: EGFR T790M confers resistance to EGFR TKI therapy.

Biomarker Criteria: Sample must match all of the following: Sample must match all of the following: EGFR T790M Sample must match one or more of the following: EGFR Sensitizing Mutations	Clinical Setting(s): Metastatic (NCCN)
	Note: EGFR T790M confers resistance to EGFR TKI therapy.

Biomarker Criteria:

Sample must match all of the following:

EGFR T790M

Clinical Setting(s): Metastatic (NCCN)

Note: EGFR T790M confers resistance to EGFR TKI therapy.

Biomarker Criteria: Sample must match all of the following: EGFR T790M	Clinical Setting(s): Metastatic (NCCN)
	Note: EGFR T790M confers resistance to EGFR TKI therapy.

Biomarker Criteria:

Sample must match all of the following:

EGFR Exon 20 Insertion

Sample must not match any of the following:

EGFR A763_Y764insFQEA

Clinical Setting(s): Metastatic (NCCN)

Biomarker Criteria:

Sample must match all of the following:

EGFR Exon 20 Insertion

Sample must not match any of the following:

EGFR A763_Y764insFQEA

Clinical Setting(s): Metastatic (NCCN)

Biomarker Criteria:

Sample must match all of the following:

MET Amplification

Clinical Setting(s): Metastatic (NCCN)

Note: MET amplification renders the EGFR kinase resistant to EGFR TKIs, leading to primary or acquired resistance.

Biomarker Criteria: Sample must match all of the following: MET Amplification	Clinical Setting(s): Metastatic (NCCN)
	Note: MET amplification renders the EGFR kinase resistant to EGFR TKIs, leading to primary or acquired resistance.

Biomarker Criteria:

Sample must match all of the following:

ROS1 Fusion

Clinical Setting(s): Metastatic (NCCN)

Note: Not recommend by NCCN in subsequent lines of therapy, in patients with ROS1 rearrangements who relapsed on crizotinib.

Biomarker Criteria: Sample must match all of the following: ROS1 Fusion	Clinical Setting(s): Metastatic (NCCN)
	Note: Not recommend by NCCN in subsequent lines of therapy, in patients with ROS1 rearrangements who relapsed on crizotinib.

Biomarker Criteria:

Sample must match one or more of the following:

KRAS Resistance Mutations

Clinical Setting(s): Metastatic (NCCN)

Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy.

Biomarker Criteria: Sample must match one or more of the following: KRAS Resistance Mutations	Clinical Setting(s): Metastatic (NCCN)
	Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy.

Biomarker Criteria:

Sample must match all of the following:

Sample must match one or more of the following:

EGFR Sensitizing Mutations

Sample must match one or more of the following:

KRAS Resistance Mutations

Clinical Setting(s): Metastatic (NCCN)

Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy.

Biomarker Criteria: Sample must match all of the following: Sample must match one or more of the following: EGFR Sensitizing Mutations Sample must match one or more of the following: KRAS Resistance Mutations	Clinical Setting(s): Metastatic (NCCN)
	Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy.

Biomarker Criteria:

Sample must match all of the following:

ALK Fusion

Clinical Setting(s): Relapse (NCCN)

Note: Not recommend by NCCN in subsequent lines of therapy, in patients with ALK rearrangements who relapsed on crizotinib.

Biomarker Criteria: Sample must match all of the following: ALK Fusion	Clinical Setting(s): Relapse (NCCN)
	Note: Not recommend by NCCN in subsequent lines of therapy, in patients with ALK rearrangements who relapsed on crizotinib.

Clinical Trials

View Clinical Trials for dacomitinib

Dacomitinib has been investigated in 9 clinical trials, of which 7 are open and 2 are closed. Of the trials investigating dacomitinib, 1 is early phase 1 (1 open), 3 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 4 are phase 2 (3 open).

ERBB2 Amplification, HER2 Overexpression, and HER2 Positive are the most frequent biomarker inclusion criteria for dacomitinib clinical trials.

Non-small cell lung carcinoma, breast carcinoma, and gastric carcinoma are the most common diseases being investigated in dacomitinib clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Dacomitinib

Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Dacomitinib

This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating dacomitinib and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:

pf-00299804, pf-00299804-03, (2e)-n-(4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)-4-piperidin-1-ylbut-2-enamide, egfr inhibitor pf-00299804, pf00299804, pf-299804, pf 00299804, dacomitinib, egfr inhibitor pf-00299804, Vizimpro

Drug Categories [2]:

Tyrosine kinase inhibitors

Drug Target(s) [2]:

DDR1, DDR2, EGFR, EPHA6, ERBB2, ERBB4, LCK, MKNK1

NCIT ID [1]:

C53398

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.

Drugs /

Back to Drugs List

Associated Genetic Biomarkers

Associated Diseases

Overview

Biomarker-Directed Therapies

Clinical Trials

Drug Details

References

About

Molecular Medicine

Content Types